23 Apr 2025
Labcorp has broadened its precision oncology portfolio with the launch of Labcorp Plasma Detect™, a blood-based test that uses whole-genome sequencing to assess molecular residual disease (MRD) and recurrence risk in stage III colon cancer patients, and the availability of PGDx elio® plasma focus Dx, the first FDA-authorized kitted pan-solid tumor liquid biopsy test for targeted treatment selection. These innovations provide oncologists with advanced tools for early detection of recurrence and comprehensive tumor profiling, especially when tissue samples are limited or unavailable. Read the full article on Clinical Lab Products to learn more about how these new solutions are transforming cancer diagnostics.